Vectibix (panitumumab)
- Region
- 🇪🇺 EU
- Active substance
- panitumumab
- Company
- Amgen Europe B.V.
- Status
- Authorised
- Therapeutic area
- Colorectal Neoplasms
- EU approval
- Mon 03 Dec 2007
- Application
- EMEA/H/C/000741
- ATC
- L01XC08
- Official record
- www.ema.europa.eu
Indication
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Regulatory milestones
No milestones recorded in the last year.
Follow Vectibix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.